ASA Monitor May 2024, Vol. 88, 27.
The U.S. Food and Drug Administration (FDA) has granted approval to Thirona’s LungQ™ AI-based clinical software, making it one of few FDA-cleared solutions able to automatically segment pulmonary structures, aiding in lung diagnosis and documentation. LungQ’s analysis improves the understanding of lung anatomy, facilitating minimally invasive treatments for diseases like COPD and lung cancer, thereby preserving healthy tissue and lung function. Acting as a lung anatomy map, LungQ enhances precision and efficiency in bronchoscopic and surgical interventions. Initially cleared in 2018, version 3.0.0 allows pulmonologists to access peripheral lung locations for diagnosis and treatment planning and assists in interventions like lung volume reduction. With this clearance, LungQ expands opportunities for precise localized treatments, including lung cancer biopsies and ablation procedures. Across Europe, the United Kingdom, and Australia, LungQ is currently used in over 600 hospitals.
Source: asamonitor.pub/4c4pq8S